Michael Vigman is an undergraduate researcher at the Nathanson lab. He is currently helping to develop novel, brain-penetrant small molecule inhibitors that can be used to treat glioblastoma (GBM). His project involves iteratively modifying a core chemical scaffold and assessing compounds based on parameters such as potency, target specificity and brain penetrance. His work includes running assays to evaluate the cellular inhibition of these compounds. Michael is a UCLA undergraduate (’24) majoring in Molecular, Cell and Developmental Biology with an intention to minor in biomedical research.